GSK plc is hoping to replicate some of the magic that another Western large pharma company did 11 years ago in partnering with Chongqing Zhifei Biological Products Co. Ltd. to distribute its top-selling vaccine in China, a move that it hopes will double its sales over the next few years.
GSK said 9 October that it had signed a partnership with Zhifei to extend the Shingrix shingles vaccine’s availability in China under an initial three-year deal set to start on 1 January 2024, for £2.5bn ($3.1bn). Under the deal, Zhifei – the largest Chinese vaccine company in terms of revenue – will have exclusive rights to import and distribute Shingrix in China, promoting it through a service network that covers more than 30,000 vaccination points across the country
Key Takeaways
-
GSK announced a partnership with Zhifei to market the Shingrix shingles vaccine in China.
-
The British drug maker pointed to Zhifei’s successful partnership with Merck for Gardasil as a model
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?